Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Present knowledge of gynecologic sarcoma management.

C F Verschraegen1, C L Edwards, H Fox

  • 1Department of Clinical Investigations, University of Texas M.D. Anderson Cancer Center, Houston, USA.

Hematology/Oncology Clinics of North America
|March 18, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Case of Hydrophobia.

Buffalo medical and surgical journal·2023
Same author

Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review. The experience of a single large specialist institution.

Clinical and experimental dermatology·2020
Same author

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.

Investigational new drugs·2008
Same author

Absence of epidermal growth factor receptor mutations in cervical cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2007

Gynecologic sarcomas are diverse cancers originating from various pelvic tissues. Understanding their distinct origins and prognoses is crucial for effective treatment strategies.

Area of Science:

  • Gynecologic oncology
  • Pathology
  • Cancer research

Background:

  • Gynecologic sarcomas are rare malignancies with varied origins and prognoses.
  • These tumors arise from mesodermal, stromal, or epithelial tissues within the pelvic organs.
  • Accurate classification is essential for determining appropriate treatment and predicting outcomes.

Purpose of the Study:

  • To define the distinct pathologies of gynecologic sarcomas based on their histologic origin.
  • To review current therapeutic knowledge for these diverse cancers.
  • To correlate treatment strategies with the intrinsic prognosis of each sarcoma type.

Main Methods:

  • Histologic classification of gynecologic sarcomas.
  • Review of existing literature on sarcoma treatment.

Related Experiment Videos

  • Analysis of prognostic factors based on tissue origin.

    • Main Results:

    • Identification of distinct sarcoma subtypes based on mesodermal, stromal, and epithelial origins.
    • Summary of current therapeutic approaches for each subtype.
    • Emphasis on the link between sarcoma histology and patient prognosis.

    Conclusions:

    • Gynecologic sarcomas represent a heterogeneous group of tumors.
    • Histologic origin is a key determinant of prognosis and influences therapeutic decisions.
    • Tailored treatment strategies based on specific sarcoma types are essential for optimal patient care.